
PRME Stock Forecast & Price Target
PRME Analyst Ratings
Bulls say
Prime Medicine Inc. is advancing its Prime Editing technology, which holds the potential to address a wide array of diseases with significant unmet medical needs, positioning the company for substantial revenue growth. Projections indicate that the PM577 drug candidate for Wilson's Disease could generate risk-adjusted revenues of $980 million by 2035, reflecting a strong path forward from $32 million in 2030. Furthermore, the promising prospects of ongoing and future programs, particularly in cystic fibrosis and other gene editing applications, suggest a favorable landscape for investor interest and potential technical success in addressing critical health challenges.
Bears say
Prime Medicine Inc. faces significant challenges that may adversely affect its stock outlook, notably the uncertainty surrounding regulatory approvals, which could result in downward revisions of risk-adjusted projections. The company's ability to recruit eligible patients for clinical programs might be hindered, further complicating its path to market. Additionally, high pricing of therapies and safety concerns related to gene editing technologies could undermine market acceptance and present fundamental risks to the overall sector.
This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares